Introduction
Post-market surveillance has evolved from a regulatory afterthought to a critical compliance imperative for medical device manufacturers. Under EU MDR Article 83, every manufacturer must "plan, establish, document, implement, maintain and update a post-market surveillance system" proportionate to device risk class. The FDA wields similar authority under 21 CFR Part 822, ordering formal PMS plans for Class II and III devices meeting criteria including serious adverse health consequences, pediatric use, or implantation exceeding one year.
2026 brings tighter EU MDR enforcement on multiple fronts. Mandatory EUDAMED submission begins May 28, Class IIb and Class III manufacturers must update PSURs annually, and Notified Body bottlenecks are creating serious transition risks for legacy device holders.
On the FDA side, Section 522 orders render non-compliant devices misbranded under federal law — exposing manufacturers to seizure, injunction, or civil penalties.
This list identifies consultants with proven regulatory depth, global reach, and cross-functional PMS capabilities. Each firm was evaluated on:
- Demonstrated EU MDR and FDA PMS expertise
- Ability to handle PSUR preparation, PMCF design, and vigilance reporting
- Track record supporting manufacturers across device risk classes
These are firms that help manufacturers build durable, inspection-ready surveillance systems — not just produce paperwork.
TL;DR
- Skipping PMS compliance risks market removal, regulatory action, and failed audits — FDA, EU MDR, and most global regulators require it
- Top consultants bring multi-market regulatory expertise, cross-device experience, and QMS integration in one engagement
- Elexes leads this list for end-to-end PMS capabilities, 50+ years collective experience, and 90% audit clearance rate
- Core services cover PMS plan development, PSUR/PMSR preparation, PMCF studies, and ongoing vigilance support
What is Post-Market Surveillance Consulting for Medical Devices?
Post-market surveillance consulting is specialized support that helps medical device manufacturers design, execute, and document systematic processes for continuously monitoring device safety and performance after market entry—covering complaint handling, adverse event reporting, PMCF studies, and PSUR preparation.
The regulatory burden makes external expertise essential. Key requirements across major markets include:
- FDA 21 CFR Part 822: Can mandate formal PMS plans for Class II/III devices, with submission required within 30 days and surveillance commencing within 15 months
- EU MDR Chapter VII: Requires PMS plans for every device class; Class IIb and Class III manufacturers must update PSURs annually, Class IIa every two years
- EUDAMED (effective May 28, 2026): Mandates digital PSUR submission for Class III and implantable devices
The documentation complexity alone exceeds most in-house capacity. EU MDR Article 84 requires PMS plans to address serious incidents, non-serious incidents, trend reporting, specialist literature, user feedback, complaints, and publicly available information about similar devices. The firms below were selected based on regulatory expertise, geographic coverage, and demonstrated track record across these requirements.
Top 10 Post-Market Surveillance Consultants for Medical Devices in 2026
These firms were selected based on regulatory depth, multi-market coverage, and documented PMS service offerings relevant to device manufacturers across size and classification. Elexes tops the list for comprehensive global PMS coverage.
Elexes
End-to-end medical device regulatory consulting firm with 50+ years of collective team experience, 250+ successful projects across 200+ product types, and a 90% audit clearance rate. Core PMS services include PMS plan development, PSUR/PMSR preparation, PMCF study design, adverse event management, and QMS integration.
The cross-functional model combines regulatory, quality, and clinical expertise within a single engagement. Flexible project-based or ongoing support models give manufacturers senior-level access without expanding headcount. Credentials include ISO 13485, ISO 14971, IEC 62304, MDSAP, and GCP, with active client coverage across USA, EU, UK, Canada, Australia, and Asia.
| Category | Details |
|---|---|
| PMS Services Offered | PMS plan, PSUR, PMSR, PMCF design, adverse event reporting, complaint handling, QMS integration, clinical evaluation support |
| Regulatory Markets Covered | FDA (21 CFR Part 822), EU MDR, Health Canada, MHRA, EMA, HSA, TGA |
| Client/Device Focus | Medical devices, IVDs, SaMD, wearables, implants, combination devices; global clients including startups and established OEMs |
NAMSA
Global medical device Contract Research Organization offering integrated regulatory and clinical services. PMS services span adverse event management, PMCF study execution, and EU MDR compliance support with in-house laboratory and testing capabilities.
NAMSA bundles PMS consulting with preclinical testing and clinical research, reducing vendor fragmentation for companies running active post-market studies. This makes them particularly strong for manufacturers who need data generation alongside documentation support.
| Category | Details |
|---|---|
| PMS Services Offered | PMCF study design and execution, adverse event reporting, PMS plan development, EU MDR documentation |
| Regulatory Markets Covered | FDA, EU MDR, IVDR; global multi-market presence |
| Client/Device Focus | Class II/III devices; manufacturers with active clinical data collection needs |
Emergo by UL
International regulatory consulting arm of UL, focused on market access and compliance across more than 20 countries. PMS services include EU MDR technical documentation, PMS plan and PSUR preparation, and vigilance reporting support.
Strong global infrastructure and local-market regulatory knowledge make Emergo well-suited for manufacturers pursuing multi-market PMS compliance in parallel. Their EU MDR readiness programs are widely referenced across the industry.
| Category | Details |
|---|---|
| PMS Services Offered | PMS plans, PSURs, PMSRs, EU MDR technical files, vigilance reporting, PMCF strategy |
| Regulatory Markets Covered | EU MDR/IVDR, FDA, Health Canada, TGA, PMDA, and additional global markets |
| Client/Device Focus | All device classes; multinational manufacturers and companies entering new markets |
ProPharma Group
Large global life sciences consulting organization offering regulatory, pharmacovigilance, and quality services across medical devices, pharma, and biologics. PMS services include complaint management systems, adverse event tracking, risk management, and regulatory submission support.
ProPharma scales through both project-based and embedded staffing models, which gives combination product manufacturers a single resource for managing device and drug PMS obligations together.
| Category | Details |
|---|---|
| PMS Services Offered | Adverse event reporting, complaint handling, CAPA management, PMS plan, risk management documentation |
| Regulatory Markets Covered | FDA, EU MDR, global regulatory bodies |
| Client/Device Focus | Medical devices, combination products, pharma-device interfaces; mid-size to large manufacturers |
BSI Group
One of the world's largest notified bodies and standards organizations. Provides PMS consulting as part of broader EU MDR conformity assessment and technical documentation services, including PSUR review guidance and PMCF adequacy assessments.
Operating as both a notified body (NB 0086) and a consulting resource, BSI gives manufacturers direct insight into what notified bodies scrutinize in PMS submissions. This dual role is particularly useful for Class IIb and Class III manufacturers preparing for conformity audits.
| Category | Details |
|---|---|
| PMS Services Offered | PSUR and PMSR review, PMCF adequacy assessment, EU MDR technical documentation, vigilance system audits |
| Regulatory Markets Covered | EU MDR/IVDR; CE marking across all device classes |
| Client/Device Focus | Class IIa/IIb/III devices requiring notified body involvement; implantable and high-risk devices |
Qserve Group
European regulatory consulting firm with deep EU MDR and IVDR expertise. Specializes in clinical evaluation, PMCF strategy, and PMS documentation for manufacturers entering or maintaining market access in the EU.
Qserve describes itself as the largest EU-focused medical device consultancy, citing 750+ successful MDR submissions. They are frequently engaged by manufacturers transitioning legacy CE-marked devices to the current MDR framework.
| Category | Details |
|---|---|
| PMS Services Offered | PMCF plan and evaluation report, CER updates, PMS plan, PMSR/PSUR, EU MDR gap assessments |
| Regulatory Markets Covered | EU MDR, IVDR; European market focus |
| Client/Device Focus | EU-focused manufacturers; devices requiring clinical evaluation update under MDR |
Regulatory Professionals Inc. (RPI / ProPharma)
Subsidiary of Premier Research and part of the ProPharma ecosystem. Provides specialized device regulatory consulting including post-approval studies, 522 PMS plan development, and FDA interaction support for companies under active PMS orders.
RPI focuses on US-market manufacturers facing FDA-ordered Section 522 surveillance requirements or post-approval study conditions on PMA devices. Direct agency communication support is included throughout the PMS process.
| Category | Details |
|---|---|
| PMS Services Offered | FDA 522 PMS plan development, post-approval study management, adverse event reporting, 510(k) and PMA post-market obligations |
| Regulatory Markets Covered | FDA (primary); US market compliance focus |
| Client/Device Focus | Class II/III device manufacturers; companies under active FDA PMS orders or post-approval study conditions |
Medpace
Global CRO with a dedicated medical device practice. Offers post-market clinical study design and management, PMCF investigation execution, and adverse event data management integrated with broader clinical trial infrastructure.
Medpace executes complex post-market clinical investigations under ISO 14155, which matters for manufacturers who need to generate new clinical evidence rather than compile existing data for PMCF requirements. According to a published post-market case study, their approach has achieved a 40% reduction in protocol deviations.
| Category | Details |
|---|---|
| PMS Services Offered | PMCF study design and management, post-market clinical investigations, adverse event data management, clinical evidence generation |
| Regulatory Markets Covered | FDA, EU MDR; global clinical trial operations |
| Client/Device Focus | Manufacturers requiring active PMCF clinical data generation; Class IIb and III devices |
IQVIA
Global healthcare data and services company with a medical device regulatory practice. PMS services include real-world evidence strategy, registry-based post-market studies, adverse event signal detection, and integrated data analytics for performance monitoring.
IQVIA's PMS approach draws on proprietary health data networks, which is particularly valuable for manufacturers needing population-level safety signal detection or comparative effectiveness data to support ongoing benefit-risk assessments.
| Category | Details |
|---|---|
| PMS Services Offered | Real-world evidence strategy, registry studies, signal detection, benefit-risk documentation, performance monitoring analytics |
| Regulatory Markets Covered | FDA, EU MDR, EMA; global data capabilities |
| Client/Device Focus | Large-scale device manufacturers; implantable and long-term use devices requiring population-level data |
Greenlight Guru
MedTech-specific quality management software and consulting platform. While primarily a software provider, its QMS platform includes purpose-built PMS workflows for complaint management, CAPA, nonconformance, and PMCF survey execution aligned with FDA and EU MDR requirements.
Greenlight Guru suits manufacturers who want to automate PMS processes through a validated digital system rather than a traditional consulting engagement. Traceability features directly connect post-market data to design controls and risk documentation.
| Category | Details |
|---|---|
| PMS Services Offered | QMS-integrated complaint management, CAPA workflows, nonconformance tracking, PMCF survey tools, EDC for post-market clinical studies |
| Regulatory Markets Covered | FDA (QSR/QMSR), EU MDR; designed for US and EU compliance |
| Client/Device Focus | Small to mid-size MedTech companies; manufacturers seeking digital PMS infrastructure |
How We Chose the Best Post-Market Surveillance Consultants
Not every regulatory consultant handles PMS well — many treat it as an add-on rather than a core discipline. Each firm on this list was assessed against consistent criteria to ensure they can support real-world surveillance obligations, not just check compliance boxes.
Evaluation criteria included documented regulatory expertise, breadth of PMS service offerings across the full lifecycle (plan → data collection → reporting → corrective action), coverage of key markets (FDA, EU MDR, Health Canada, MHRA), and evidence of relevant client engagements or certifications.
Common selection mistakes to avoid:
- Choosing a generalist firm without dedicated PMS or medical device experience
- Selecting based on brand name alone without confirming device-class-specific track record
- Overlooking integration capabilities—PMS linked to QMS and clinical reduces coordination costs
Key selection factors:
- Regulatory market coverage — A firm strong in FDA 522 orders may lack EU MDR PSUR depth. Confirm multi-market capability before committing.
- Service integration — PMS connected to your QMS cuts duplication. PMCF feeding directly into CER updates under EU MDR Annex XIV saves meaningful time.
- Engagement model flexibility — Project-based engagements suit discrete PSUR updates; retainer or embedded staff models work better for ongoing vigilance reporting and complaint management.
- Deliverable transparency — Missed PSUR deadlines trigger notified body scrutiny and can delay recertification. Under EU MDR Article 86, timelines are regulatory obligations, not suggestions.
Conclusion
Post-market surveillance is no longer a compliance afterthought. Under EU MDR and increasing FDA scrutiny, a poorly managed PMS program is one of the fastest ways to lose market access for a device that already cleared its approval hurdle.
Evaluate consultants against your specific device class, target markets, and internal capability gaps before committing. The right partner for a Class I EU MDR device looks very different from the right partner for a Class III FDA PMA with a 522 surveillance order.
For manufacturers seeking an end-to-end PMS partner, Elexes combines regulatory, quality, and clinical expertise under one engagement across flexible models and global markets. Contact Elexes to map your PMS program requirements to the right engagement model.
Frequently Asked Questions
How much does post-market surveillance cost?
Costs depend on device class and scope: documentation-only support for Class I devices typically runs $5,000–$15,000 per year, while full PMCF study management for Class III devices can exceed $100,000. Outsourcing is generally more cost-effective than building an internal team, with options for project-based or retainer pricing.
Who does post-marketing surveillance?
The primary legal obligation for PMS falls on the medical device manufacturer (or their Authorized Representative in the EU), who must either maintain internal PMS capabilities or engage a qualified external consultant or CRO to execute and document the required activities on their behalf. Outsourcing does not transfer legal responsibility.
What is the difference between PMCF and PMS?
PMS (Post-Market Surveillance) is the broader system for continuously monitoring a device's safety and performance after market entry. PMCF (Post-Market Clinical Follow-up) is a specific clinical activity within PMS, required under EU MDR Annex XIV. It proactively collects and evaluates clinical data to confirm safety claims, identify unknown side effects, and assess emerging risks.
Is PMCF part of clinical evaluation?
Yes, under EU MDR, PMCF is formally part of the clinical evaluation process. PMCF data feeds directly into updates of the Clinical Evaluation Report (CER), and manufacturers must either conduct PMCF activities or provide documented scientific justification for why PMCF is not necessary for their specific device.
What are the four types of surveillance?
Medical device regulation references four surveillance types:
- Reactive surveillance — responds to adverse events and complaints
- Proactive surveillance — systematically collects data from literature, registries, and user feedback
- Active surveillance — structured studies initiated by manufacturers or ordered by regulators
- Passive surveillance — monitors spontaneously reported adverse events through systems like FDA's MAUDE database
